The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Q3 2024 Management View CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Citi analysts adjusted their outlook on Eisai Co Ltd (OTC:ESAIY). (4523:JP) (OTC: ESALY), reducing the price target from JPY6,000 to JPY5,000, while continuing to endorse the stock with a Buy rating.

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the monthly intravenous (IV) maintenance regimen of Leqembi ® (lecanemab-irmb) for early ...

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...

Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for Leqembi, which exceeded consensus estimates.

Key contributors included LEQEMBI with a 28.1 billion yen increase, Lenvima with 24.9 billion yen growth, and Dayvigo up by 9.3 billion yen. Naito emphasized significant milestones for LEQEMBI ...